To date, pramlintide is the only commercially available amylin analog (administered subcutaneously at mealtime) approved by the FDA as an adjunctive treatment to insulin therapy in patients with T1D and T2D [171,172,173]. This evidence concerns the gene INS and type 1 diabetes mellitus.